The Lawyers Weekly looks at the legal problems that will arise as a result of the pathway that is now built from biosimilars. There is anticipated legal battles that legal battles will rage due to lack of regulation in the industry. Currently, biosimilars aren't required to have clinical trials, but they are not exact molecular duplicates like generic drugs. There are currently many discussions happening over whether or not biosimilars should have to undergo clinical trials. Our LinkedIn Group is currently debating this topic.
Join the Business of Biosimilars LinkedIn group and find out what our members have to say about whether or not biosimilars should be required to go through clinical trials.
|
Share this article with your social network, just click below to share now!
|
|
|
The global synthetic biology market is supposed to reach $13.4 billion by 2019. A recent study from Transparency Market Research shows that...
Oren Levy from Karp Lab gave an excellent talk called “MSCs on Steriods” last month at Biotech Week Boston. Oren's research focus is &q...
If you blink you will most likely miss some major design, invention or discovery in the robotics industry. The future is definitely here, an...
No comments :
Post a Comment